Live Breaking News & Updates on தலை ஆஃப் உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் சந்தைப்படுத்தல்|Page 2

Stay updated with breaking news from தலை ஆஃப் உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் சந்தைப்படுத்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Evotec Accelerates Access to Biologic Therapeutics with Initiation of Manufacturing Facility in Toulouse

Evotec Accelerates Access to Biologic Therapeutics with Initiation of Manufacturing Facility in Toulouse
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France General , United States , Evotec Toulouse , Toulouse Metropole , Werner Lanthaler , Craig Johnstone , Sanofi Evotec , Volker Braun , Carole Delga , Jean Luc Moudenc , Evotec Biologics , Gabriele Hansen , United States Department Of Defense , Boehringer Ingelheim , Melinda Gates Foundation , Evotec Se Frankfurt Stock Exchange , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Health Campus Of The , Novo Nordisk , Frankfurt Stock Exchange , Campus Curie , United States Department , Occitanie Region , Chief Executive Officer , Chief Operating Officer ,

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
DGAP-News: Evotec SE
/ Key word(s): Miscellaneous
19.04.2021 / 08:31
The issuer is solely responsible for the content of this announcement.
EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801
KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC
EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC )
EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES ....

New South Wales , Volker Braun , Gabriele Hansen , Kazia Therapeutics Limited , Simcere Pharmaceutical Company , Boehringer Ingelheim , Evotec Se Frankfurt Stock Exchange , Distribution Services , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Office Of Kazia , Novo Nordisk , Frankfurt Stock Exchange , Cord Dohrmann , Chief Scientific Officer , James Garner , Chief Executive Office , Therapeutics Limited , Orphan Drug Designation , Fast Track Designation , Rare Pediatric Disease Designation , Orphan Designation , Greater China , Simcere Pharmaceutical , Global Corporate Communications , Global Investor Relations ,

Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC
EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC )
EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES
HAMBURG, GERMANY / ACCESSWIRE / April 19, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited ( Kazia , ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec s oncology project EVT801. ....

New South Wales , Volker Braun , Gabriele Hansen , Kazia Therapeutics Limited , Simcere Pharmaceutical Company , Boehringer Ingelheim , Evotec Se Frankfurt Stock Exchange , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Office Of Kazia , Novo Nordisk , Frankfurt Stock Exchange , Cord Dohrmann , Chief Scientific Officer , James Garner , Chief Executive Office , Therapeutics Limited , Orphan Drug Designation , Fast Track Designation , Rare Pediatric Disease Designation , Orphan Designation , Greater China , Simcere Pharmaceutical , Global Corporate Communications , Global Investor Relations , புதியது தெற்கு வேல்ஸ் ,

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 – Health Technology Net

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 – Health Technology Net
digitalfacility.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalfacility.com Daily Mail and Mail on Sunday newspapers.

New South Wales , Volker Braun , Gabriele Hansen , Kazia Therapeutics Limited , Simcere Pharmaceutical Company , Boehringer Ingelheim , Evotec Se Frankfurt Stock Exchange , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Office Of Kazia , Novo Nordisk , Frankfurt Stock Exchange , Cord Dohrmann , Chief Scientific Officer , James Garner , Chief Executive Office , Therapeutics Limited , Orphan Drug Designation , Fast Track Designation , Rare Pediatric Disease Designation , Orphan Designation , Greater China , Simcere Pharmaceutical , Global Corporate Communications , Global Investor Relations , புதியது தெற்கு வேல்ஸ் ,

PRESS RELEASE: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Message :
Required fields
DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
2021-04-19 / 08:31
The issuer is solely responsible for the content of this announcement.
=
. EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY
ASSET EVT801
. KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC
. EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC )
. EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO
RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES ....

New South Wales , Volker Braun , Manfred Eigen , Gabriele Hansen , English Company , Kazia Therapeutics Limited , Boehringer Ingelheim , Distribution Services , Tradegate Exchange , Head Of Global Corporate Communications Marketing , News Service , Bristol Myers Squibb , Simcere Pharmaceutical Company , Evotec Se Frankfurt Stock Exchange , Office Of Kazia , Novo Nordisk , Kazia Therapeutics , Frankfurt Stock Exchange , Cord Dohrmann , Chief Scientific Officer , James Garner , Chief Executive Office , Therapeutics Limited , Orphan Drug Designation , Fast Track Designation , Rare Pediatric Disease Designation ,